Beyond safety: rethinking concomitant radiotherapy and trastuzumab deruxtecan in metastatic breast cancer — from feasibility to precision practice

Study limitation reported by the research below: “No sample size is applicable — the 'largest real-world evidence' cited belongs to the Visani et al. study being critiqued, not this paper.”